转移复发时雌激素受体丢失的管腔样乳腺肿瘤的临床病理特征与生存结局:一项病例对照研究
该嵌套病例对照研究比较了51例原发ER+/HER2-且转移灶三阴性(LUM-TN)患者与50例配对早期转移ER+/HER2-(LUM-LUM)及49例三阴性(TN-TN)乳腺癌患者的临床病理特征与结局。LUM-TN远处无转移生存与LUM-LUM相似但显著长于TN-TN,转移后生存与TN-TN相当且显著短于LUM-LUM,高TILs与ER丢失患者更差结局相关。
要点
- LUM-TN肿瘤ER表达低于LUM-LUM,但分级和Ki67低于TN-TN。
- LUM-TN远处无转移生存与LUM-LUM相似,显著长于TN-TN。
- LUM-TN转移后生存与TN-TN相当,显著短于LUM-LUM。
核心结论
- 转移复发时ER丢失的乳腺肿瘤具有介于转移性管腔样和原发三阴性肿瘤之间的特征和结局。
- 关于ER表达丢失生物学机制的研究正在进行中。
研究设计与样本
- 嵌套病例对照研究,比较51例原发ER+/HER2-且配对转移灶三阴性(LUM-TN)患者与50例配对早期转移ER+/HER2-(LUM-LUM)及49例三阴性(TN-TN)乳腺癌患者。
- 间质肿瘤浸润淋巴细胞(TILs)按TILs工作组建议以连续变量和离散变量( cutoff 20%、40%)评估。
主要发现
- LUM-TN肿瘤ER表达低于LUM-LUM肿瘤,但分级和Ki67低于TN-TN病例。
- LUM-TN与LUM-LUM队列的中位远处无转移生存相似,但显著长于TN-TN病例(log-rank P < 0.001)。
- LUM-TN与TN-TN队列从转移复发时起的生存相当,显著短于LUM-LUM肿瘤患者(log-rank P < 0.001)。
- 高TILs与ER丢失患者更差结局相关(P < 0.001)。
关键数值与推荐
- LUM-TN队列51例,LUM-LUM队列50例,TN-TN队列49例。
- TILs离散变量 cutoff 为20%和40%。
- 远处无转移生存比较log-rank P < 0.001;转移后生存比较log-rank P < 0.001;高TILs与结局关联P < 0.001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Estrogen receptor (ER) loss at metastatic relapse occurs in up to 20% of luminal-like primary breast tumors. Data about clinicopathological features associated with ER loss and its prognostic significance are limited. METHODS: In a nested-case-control study, we compared clinicopathological characteristics and clinical outcomes between a cohort of 51 patients with primary ER+ /HER2- and paired triple-negative metastasis (LUM-TN) and two control cohorts of paired early-metastatic ER+ /HER2- (LUM-LUM, n = 50) and triple-negative (TN-TN, n = 49) breast cancers. Stromal tumor-infiltrating lymphocytes (TILs) were assessed according to the TILs Working Group recommendations as continuous and discrete variables with cutoffs (20%, 40%). RESULTS: LUM-TN tumors had lower ER expression than LUM-LUM tumors, but lower grade and Ki67 than TN-TN cases. Median distant-metastasis free survival was similar for LUM-TN and LUM-LUM cohorts, but significantly longer than in TN-TN cases (log-rank P < 0.001). LUM-TN and TN-TN cohorts had a comparable survival from the time of metastatic recurrence, which was significantly shorter than in patients with LUM-LUM tumors (log-rank P < 0.001). High TILs were associated with worse outcomes in patients with ER loss (P < 0.001). CONCLUSIONS: Breast tumors with ER loss at metastatic relapse have intermediate features and outcomes compared with metastatic luminal-like and ab initio triple-negative tumors. Further investigation on the biological mechanisms underpinning the loss of ER expression is ongoing.
引用
- Morganti S, Marra A, Gandini S, et al. Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study. Eur J Cancer. 2023. PMID: 37890353. doi:10.1016/j.ejca.2023.113397
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。